Recommendations developed for management of hidradenitis suppurativa

New evidence-based guidelines from the American Academy of Dermatology and Hidradenitis Suppurativa Foundation outline 37 recommendations for managing hidradenitis suppurativa. Strong recommendations include biologics such as adalimumab, bimekizumab, infliximab and secukinumab, along with routine pain assessment.